EX-FILING FEES 4 tm2220235d1_ex-filingfees.htm EX-FILING FEES

Exhibit 107

 

Calculation of Filing Fee Table

 

Form S-8

(Form Type)

 

Idera Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered Securities

 

Newly Registered Securities
  Security
Type
  Security
Class
Title(1)
  Fee
Calculation
or Carry
Forward
Rule
  Amount
Registered
(1)
  Proposed
Maximum
Offering
Price
Per Unit
(2)
  Proposed
Maximum
Aggregate
Offering Price
(2)
  Fee Rate  Amount of
Registration
Fee
  Carry
Forward
Form
Type
  Carry
Forward
File
Number
  Carry
Forward
Initial
Effective
Date
  Filing Fee
Previously
Paid in
Connection
with Unsold
Securities to
be Carried
Forward
 
Fees to be Paid Equity   Common Stock, $0.001 par value   Rule 457(c) and Rule 457 (h)    4,600,000  $0.44  $2,024,000.00   $92.70 per $1,000,000.00  $187.62   -   -   -   - 
Fees Previously Paid -   -   -    -   -   -   -   -   -   -   -   - 
Carry Forward Securities
Carry Forward Securities -   -   -   -   -   -   -   -   - 
  Total Offering Amounts      $2,024,000.00      $187.62                 
  Total Fees Previously Paid               -                 
  Total Fee Offsets               -                 
  Net Fee Due              $                  

 

(1)Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 shall also cover any additional shares of the registrant’s common stock, $0.001 par value (the “Common Stock”) which become issuable under the Idera Pharmaceuticals, Inc. 2013 Stock Incentive Plan, as amended, by reason of any stock dividend, stock split, recapitalization, or any other similar transaction effected without the receipt of consideration which results in an increase in the number of outstanding shares of Common Stock.
(2)Estimated solely for the purpose of determining the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act, based on the average of the high and low prices of the Common Stock as reported on The Nasdaq Capital Market on June 30, 2022.